Unpublished Research Series 

The reports included in the NRG Oncology Unpublished Research Series reflect the rare instances, when analyses of NRG Oncology data have not been able to be published in a peer-reviewed journal.  In order to make those results available in manuscript form, for downloading and citation, they are posted here. The majority of our research has been published in a peer-reviewed journal and can be found using the NRG Oncology Publication Search or in PubMed.
STUDY NUMBER DISEASE SITE TITLE / AUTHOR LINE LINK TO MANUSCRIPT VERSION DATE UPLOAD DATE
 NRG-RTOG 0212 AND 0214  Lung Gondi V, Paulus R, Bruner DW, Gore EM, Wolfson AH, Werner-Wasik M, Sun AY, Videtic GMM, Suntharalingam M, Jeter MD, Yeh AM, Bove JA, Robinson CG, Ahmed S, Gopaul DD, Gaspar LE, Dominello MM, Choy H, Movsas B. Prognostic Significance of Decline in Patient-Reported Quality of Life during Early Lung Cancer Survivorship: Pooled Secondary Analysis of RTOG 0212 and 0214.   MANUSCRIPT  24-NOV-2020  20-FEB-2023
 NRG-RTOG 0229  Lung

Krasna MJ, Paulus R, Suntharalingam M, Edelman MJ, Decker RH, McCabe V, Garces YI, Dobelbower MC,  Elizabeth E, Huang TW, Choy H. Surgical Resection Following Neoadjuvant Concurrent Chemotherapy and High Dose Radiotherapy for Stage III NSCLC: Results of NRG Oncology RTOG 0229.

   MANUSCRIPT  21-JUN-2017  20-FEB-2023 
 NRG-RTOG 0241  Lung Langer CJ, Paulus R, Werner-Wasik M, Lilenbaum R, Samuels M, Osmundsen E, Koprowski C, Johnson F, Spencer SA, Choy H. Radiation Therapy Oncology Group (RTOG) 0241: Phase I study of irinotecan and cisplatin in combination with twice daily thoracic radiotherapy (45Gy) or once daily thoracic radiotherapy (70Gy) in patients with limited stage small cell carcinoma of the lung (LD-SCLC).   MANUSCRIPT  13-AUG-2015  7-JUN-2023
 NRG-RTOG 0244  Head & Neck  Jha N, Deshmukh S, Seikaly H, Jacobs JR, McEwan AJ, Ryu S, Clausen C, Chakravarti A, Harris JR, Sharma AK, Pochini C, Markoe AM, Kim H, Koyfman S, Le Q. Results of Quality of Life for Phase II NRG Oncology RTOG 0244 Study Using Submandibular Salivary Gland Transfer Procedure for Prevention of Radiation-Induced Xerostomia in Head and Neck Cancer Patients.   MANUSCRIPT  29-MAY-2015  31-DEC-2022
 NRG-RTOG 0418  Gynecologic Jhingran A, Witner K, Portelance L, Miller BE, Salehpour MR, Gaur R, Souhami L, Small W, Gaffney D. Efficacy and Safety of IMRT After Surgery in Patients with Endometrial Cancer: RTOG 0418 Phase II Study   MANUSCRIPT  2-MAY-2016  20-FEB-2023
 NRG-RTOG 0418  Gynecologic Portelance L, Moughan J, Jhingran A, Miller BE, Salehpour MR, D'Souza D, Haddock MG, Rotman M, Souhami L, Smith M, Eisbruch A, Poppe M, Gaffney DK. Phase II Study on the Feasibility of Intensity Modulated Radiation Therapy (IMRT) in a Mulit-Institutional Setting for Post Operative Concomitant Chemoradiation for Patients with Cervical Cancer. NRG Oncology/RTOG 0418. Primary and Secondary Endpoint Results.   MANUSCRIPT  7-MAR-2018  20-FEB-2023
 NRG-RTOG 0630  Sarcoma Wilmoth M, Harris J, Wang D, Kirsch DG, Okuno SH, Eisenberg BL, Kane JM III, Li XA, Lucas D, Kraybill W, Freeman CR, Finkelstein SE, Hitchcock Y, Salerno KE, Bedi M, Godette KD, Peterson IA, Movsas B. Quality of Life Outcomes Associated with Primary Soft Tissue Sarcomas of the Extremity.    MANUSCRIPT  20-DEC-2019  13-JUL-2023
 NRG-RTOG 0825  Brain Pugh SL, Mao J, Gilbert MR, Wefel JS, Armstrong TS, Anderson S. Joint Models for the Analysis of Patient Reported Outcome and Neurocognitive Function Data in the Presence of Non-Ignorable Missing Data.   MANUSCRIPT  2-SEP-2022  4-JUN-2025
 NRG-RTOG 9410  Lung Langer CJ, Hu C, Curran WJ, Komaki RR, Lee JS, Cox JD, McGarry RC, Padula GDA, Faria SL, Smith CJ, Michalski JM, Wener-Wasik M, Sause WT, Kim HE, Millenson MM, Kunos CA, Paulus R, Bradley JD. Do Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer Benefit from Combined Modality Therapy? A Secondary Analysis of RTOG 94-10   MANUSCRIPT  16-APR-2015  20-FEB-2023
 NRG-RTOG 9704  GI Heestand GM, Murphy JD, Moughan J, Regine W, Luo J, Hellendag MG, Kunz PL, Fisher GA, Cuha C, Kozak M, Mowat R, Gaur R, Buyyounouski M, Chen Y, Chang DT, Koong AC. A Novel Biomarker Panel Examining Response to Adjuvant Pancreatic Cancer Therapy in NRG Oncology RTOG 9704.   MANUSCRIPT  22-SEP-2015  20-FEB-2023
 NRG-RTOG-9704  Pancreas Ben-Josef E, Winter K, Regine WF, Timmers C, Robb R, DiPetrillo TA, Leasure NC, Mowat R, Kim H, Koenig J, Narayan S, Bush DA, Fromm M, Moughan J, Guha C, Williams T. ß-catenin is independently associated with outcome in pancreatic ductal adenocarcinoma: An analysis of NRG Oncology/RTOG 9704.    MANUSCRIPT  14-APR-2025  1-APR-2025
 NRG-RTOG Clinical Trials Recruitment  Multi Hanisch LJ, Rearden J, James J, Thomas T, Gaffney D, NEading J, Neimanis D, Stern J, Consoli SJ, Pugh SL, Bruner DW. Identification of Patient-Level Barriers and Facilitators to NRG Oncology/RTOG Clinical Trials Recruitment   MANUSCRIPT  14-NOV-2017  20-FEB-2023
NSABP B-24 Breast Julian T, Vicini F, Costantino JP, Duggal S, Wickerham L, Arthur DW, Land SR, Wapnir IL, Dignam JJ, Mamounas EP, White JR, Womark N. Is Boost Therapy Necessary in the Treatment of DCIS with Breast-Conserving Therapy?   MANUSCRIPT  1-AUG-2016  16-MAY-2023

 

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.